| ObjectiveTo evaluate the efficacy and safety of initiating insulin therapy with insulin detemir once-daily in oral antidiabetic drug-treated patients with type 2 diabetes mellitus(T2DM)whose blood glucose is not yet up to the standard.Methods20 subjects with T2DM, including 11 men and 9 women, were enrolled in this study, averaged 56±6.82 years old(ranging from 48~70 years old).Insulin detemir were given to all patients in oral antidiabetic drug-treated. During the treatment, the dosages of insulin analogue were adjusted according to self-recorded daily 7-point blood glucose. Compared with pretherapy, at the end of 12 and 24 weeks therapy, HbA1C, blood glucose, hypoglycemic events, allergic reaction, body weight was measured.Results1. The HbA1C of pretherapy and 12, 24-week-ending therapy are 7.13±1.05, 7.01±0.94, 7.00±0.95, respectively. Compared with pretherapy, at the end of 12 and 24 weeks treatment HbA1C was decreased, but there's no significant difference (P=0.553, 0.545). There was no significant difference between 12 and 24-week-ending therapy(P=0.970).2. Compared with pretherapy,at the end of 12 and 24weeks treatment, the 7-point blood glucose had no significantly reducement (P>0.05). There was no significant difference between 12 and 24-week-ending therapy (P>0.05).3. There was no hypoglycemic event or allergic reaction during the treatment .4. The body weight of pretherapy and 12,24-week-ending therapy are 67.39±10.15, 67.05±10.18, 67.21±10.25, respectively. Compared with pretherapy,at the end of 12 and 24weeks treatment, the weight had no statistics significance (P=0.331, 0.187). There was no significant difference of body weight between 12 and 24-week-ending therapy (P=0.331).ConclusionsInsulin detemir certainly reduce HbA1C in T2DM patients effectively. Insulin detemir not only don't increase hypoglycemic events, allergic reaction, but also don't increase body weight. So it is one of an ideal choice for T2DM patients to control blood glucose. |
PDF Full Text Request